Memphasys Limited (ASX: MEM) has announced the appointment of Ms Lindley Edwards as Non-Executive Chairperson, effective 23 November 2024. Her appointment comes as the company advances its flagship Felix™ System towards commercialisation and progresses other innovative biotechnology projects.
Edwards, a seasoned executive with over 30 years’ experience in financial services, corporate governance, and technology commercialisation, succeeds Mr Robert Cooke, who is stepping down to focus on other commitments. Edwards’ extensive background in mergers, acquisitions, and strategic growth makes her a pivotal addition to Memphasys as it prepares for significant milestones.
A Visionary Leader at a Critical Juncture
Edwards, currently the CEO of AFG Venture Group, brings a strong track record in corporate governance and executing growth strategies across diverse industries. Her expertise aligns seamlessly with Memphasys’ objectives, particularly as the company seeks to launch the Felix™ System, a proprietary sperm separation technology, in global markets.
“The Felix™ System and RoXsta™ System present exciting opportunities for the company to expand its impact in the global fertility and biotechnology markets,” Edwards remarked. Her academic credentials, which include advanced studies in digitisation, innovation, and corporate governance, further strengthen Memphasys’ leadership bench.
Lindley Edwards, incoming Chairperson
Steering the Felix™ System to Commercialisation
The Felix™ System, which has reached 95% recruitment in its pivotal clinical trial, is a revolutionary sperm selection tool designed to improve assisted reproductive outcomes. Memphasys plans to conclude the trial by the end of 2024, with results underpinning regulatory submissions for CE mark approval in Europe and subsequent entry into other major markets, including India and Australia.
Dr David Ali, Memphasys’ CEO, welcomed Edwards’ appointment, emphasising the timing:
“Lindley’s deep expertise in governance and strategic partnerships comes at a pivotal time as we prepare for the next phase of Memphasys’ growth. Her leadership will be invaluable as we advance our innovative technologies towards global commercialisation.”
A Broader Innovation Agenda
In addition to the Felix™ System, Memphasys is advancing the RoXsta™ System, a tool for measuring oxidative stress with applications in both human and animal health. The RoXsta™ System recently achieved provisional patent approval, reflecting the company’s commitment to diversifying its portfolio and expanding its impact in reproductive biotechnology.
Strengthening Strategic Foundations
Under Edwards’ leadership, Memphasys is poised to capitalise on its innovative technologies and strategic market opportunities. The company is actively pursuing partnerships with distributors and investors, leveraging its clinical trial progress and regulatory advancements to drive commercial growth.
As Memphasys approaches critical milestones, Edwards’ appointment signals a strong commitment to governance, strategic execution, and global market leadership. With the Felix™ System nearing regulatory submission and commercial launch, the company is well-positioned to deliver transformative solutions in fertility and biotechnology.
